4-methyl-7-(2-{[2-(piperidin-1-yl)ethyl]sulfanyl}ethoxy)-2H-chromen-2-one



Compound IDCDAMM00145
Common name4-methyl-7-(2-{[2-(piperidin-1-yl)ethyl]sulfanyl}ethoxy)-2H-chromen-2-one
IUPAC name4-methyl-7-[2-(2-piperidin-1-ylethylsulfanyl)ethoxy]chromen-2-one
Molecular formulaC19H25NO3S

Experimental data

Retention time20.9
Adduct[M+H]+
Actual mz348.163
Theoretical mz348.163
Error0.02
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score4.6066

Identifiers and class information

Inchi keyGKQOQFXNJFVBLL-UHFFFAOYSA-N
SmilesCC1=CC(=O)OC2=C1C=CC(=C2)OCCSCCN3CCCCC3
SuperclassPhenylpropanoids and polyketides
ClassCoumarins and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)7
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)347.471
Computed dipole moment(dipole)8.929
Total solvent accessible surface area (SASA)674.204
Hydrophobic component of SASA (FOSA)411.547
Hydrophilic component of SASA (FISA)77.333
Pie component of the SASA (PISA)149.117
Weakly polar component of the SASA (WPSA)36.208
Total solvent accesible volume (volume)1172.79
Number of hydrogen bond donors (donorHB)0
Number of hydrogen bond acceptors (accptHB)5.75
Free energy of solvation of dipole (dip^2/V)0.0679754
Index of cohesive interaction in solids (ACxDN^.5/SA)0
Globularity descriptor (glob)0.797726
Predicted polarizability in cubic angstroms (QPpolrz)37.71
Predicted hexadecane/gas partition coefficient (QPlogPC16)10.98
Predicted octanol/gas partition coefficient (QPlogPoct)15.981
Predicted water/gas partition coefficient (QPlogPw)7.014
Predicted octanol/water partition coefficient (QPlogPo/w)3.397
Predicted aqueous solubility (QPlogS)-3.781
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.372
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.242
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)456.512
Predicted brain/blood partition coefficient (QPlogBB)-0.181
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)370.24
Predicted skin permeability, log Kp (QPlogKp)-3.81
PM3 calculated ionization potential (IP(ev))9.062
PM3 calculated electron affinity (EA(eV))0.856
Number of likely metabolic reactions (#metab)3
Prediction of binding to human serum albumin (QPlogKhsa)0.187
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)94.433
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)53.789
Number of nitrogen and oxygen atoms (#NandO)4
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q9Y5N1HRH3Histamine H3 receptorT64765SEA
P22303ACHEAcetylcholinesteraseT30082SEA
Q12809KCNH2HERGT20251SEA
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
Q99720SIGMAR1Sigma opioid receptorT46360SEA
P09960LTA4HLeukotriene A4 hydrolaseT03691SEA
P21397MAOAMonoamine oxidase AT83875SEA
P27338MAOBMonoamine oxidase BT83011SEA
P28223HTR2ASerotonin 2a (5-HT2a) receptorT32060SEA
P28335HTR2CSerotonin 2c (5-HT2c) receptorT83813SEA
P31645SLC6A4Serotonin transporter (by homology)T27812SEA
P41595HTR2BSerotonin 2b (5-HT2b) receptorT31204SEA
P15538CYP11B1Cytochrome P450 11B1T84621SEA
P19099CYP11B2Cytochrome P450 11B2T59056SEA
Q92731ESR2Estrogen receptor betaT80896SEA
P11511CYP19A1Cytochrome P450 19A1T13260SEA
P35367HRH1Histamine H1 receptorT77913SEA
P03372ESR1Estrogen receptor alphaT02506SEA
P21918DRD5Dopamine D5 receptorT46828SEA
P06276BCHEButyrylcholinesteraseT99799SEA
P35348ADRA1AAlpha-1a adrenergic receptorT92609SEA
P05186ALPLAlkaline phosphatase, tissue-nonspecific isozymeT09538SEA
P08842STSSteryl-sulfataseT33489SEA
Q9NR96TLR9Toll-like receptor (TLR7/TLR9)T11451SEA
P46098HTR3ASerotonin 3a (5-HT3a) receptorT64591SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P78527PRKDCDNA-dependent protein kinaseT81735SEA
P28074PSMB5Proteasome Macropain subunit MB1T49031SEA
P22460KCNA5Voltage-gated potassium channel subunit Kv1.5T17569SEA
P22001KCNA3Voltage-gated potassium channel subunit Kv1.3T76914SEA
P51679CCR4C-C chemokine receptor type 4T06955SEA
Q92952KCNN1Small conductance calcium-activated potassium channel protein 1T11911SEA
P47901AVPR1BVasopressin V1b receptorT59881SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
Q9H2S1KCNN2Small conductance calcium-activated potassium channel protein 2T86271SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA
Q09470KCNA1Voltage-gated potassium channel Kv1.1T85272SEA
Q96RP8KCNA7Voltage-gated potassium channel Kv1.7T84737SEA
P22459KCNA4Voltage-gated A-type potassium channelT15665SEA
P16389KCNA2Voltage-gated potassium channel Kv1.2T19492SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T64765DI0392Somnolence[ICD-11: MG42]Q9Y5N1HRH3
T30082DI0025Alzheimer disease[ICD-11: 8A20]P22303ACHE
T30082DI0166Glaucoma[ICD-11: 9C61]P22303ACHE
T30082DI0282Myasthenia gravis[ICD-11: 8C6Y]P22303ACHE
T30082DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P22303ACHE
T30082DI0332Pediculosis[ICD-11: 1G00]P22303ACHE
T30082DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P22303ACHE
T20251DI0175Heart failure[ICD-11: BD10-BD1Z]Q12809KCNH2
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T46360DI0105Cough[ICD-11: MD12]Q99720SIGMAR1
T03691DI0012Acute myeloid leukaemia[ICD-11: 2A60]P09960LTA4H
T83875DI0117Depression[ICD-11: 6A70-6A7Z]P21397MAOA
T83875DI0331Parkinsonism[ICD-11: 8A00]P21397MAOA
T83011DI0115Dementia[ICD-11: 6D80-6D8Z]P27338MAOB
T83011DI0117Depression[ICD-11: 6A70-6A7Z]P27338MAOB
T83011DI0190Hypertension[ICD-11: BA00-BA04]P27338MAOB
T83011DI0243Malaria[ICD-11: 1F40-1F45]P27338MAOB
T83011DI0264Migraine[ICD-11: 8A80]P27338MAOB
T83011DI0331Parkinsonism[ICD-11: 8A00]P27338MAOB
T32060DI0009Acute diabete complication[ICD-11: 5A2Y]P28223HTR2A
T32060DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P28223HTR2A
T32060DI0073Cerebral ischaemia[ICD-11: 8B1Z]P28223HTR2A
T32060DI0270Mood disorder[ICD-11: 6A60-6E23]P28223HTR2A
T32060DI0331Parkinsonism[ICD-11: 8A00]P28223HTR2A
T32060DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28223HTR2A
T32060DI0370Schizophrenia[ICD-11: 6A20]P28223HTR2A
T83813DI0117Depression[ICD-11: 6A70-6A7Z]P28335HTR2C
T83813DI0264Migraine[ICD-11: 8A80]P28335HTR2C
T83813DI0308Obesity[ICD-11: 5B80-5B81]P28335HTR2C
T83813DI0324Pain[ICD-11: MG30-MG3Z]P28335HTR2C
T83813DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28335HTR2C
T27812DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P31645SLC6A4
T27812DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P31645SLC6A4
T27812DI0087Chronic pain[ICD-11: MG30]P31645SLC6A4
T27812DI0096concerning food/fluid intake symptom[ICD-11: MG43]P31645SLC6A4
T27812DI0101Corneal disease[ICD-11: 9A76-9A78]P31645SLC6A4
T27812DI0105Cough[ICD-11: MD12]P31645SLC6A4
T27812DI0117Depression[ICD-11: 6A70-6A7Z]P31645SLC6A4
T27812DI0264Migraine[ICD-11: 8A80]P31645SLC6A4
T27812DI0301Nicotine use disorder[ICD-11: 6C4A]P31645SLC6A4
T27812DI0308Obesity[ICD-11: 5B80-5B81]P31645SLC6A4
T27812DI0324Pain[ICD-11: MG30-MG3Z]P31645SLC6A4
T31204DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P41595HTR2B
T31204DI0117Depression[ICD-11: 6A70-6A7Z]P41595HTR2B
T31204DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P41595HTR2B
T31204DI0354Psychotic disorder[ICD-11: 6A20-6A25]P41595HTR2B
T84621DI0062Breast cancer[ICD-11: 2C60-2C6Y]P15538CYP11B1
T84621DI0108Cushing syndrome[ICD-11: 5A70]P15538CYP11B1
T59056DI0190Hypertension[ICD-11: BA00-BA04]P19099CYP11B2
T80896DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q92731ESR2
T80896DI0108Cushing syndrome[ICD-11: 5A70]Q92731ESR2
T80896DI0254Menopausal disorder[ICD-11: GA30]Q92731ESR2
T80896DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q92731ESR2
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T77913DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P35367HRH1
T77913DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P35367HRH1
T77913DI0063Breathing abnormality[ICD-11: MD11]P35367HRH1
T77913DI0099Conjunctiva disorder[ICD-11: 9A60]P35367HRH1
T77913DI0105Cough[ICD-11: MD12]P35367HRH1
T77913DI0117Depression[ICD-11: 6A70-6A7Z]P35367HRH1
T77913DI0136Episodic vestibular syndrome[ICD-11: AB31]P35367HRH1
T77913DI0173Headache[ICD-11: 8A80-8A84]P35367HRH1
T77913DI0214Insomnia[ICD-11: 7A00-7A0Z]P35367HRH1
T77913DI0272Morning sickness disorder[ICD-11: SC00]P35367HRH1
T77913DI0292Nasopharyngitis[ICD-11: CA00]P35367HRH1
T77913DI0293Nausea/vomiting[ICD-11: MD90]P35367HRH1
T77913DI0331Parkinsonism[ICD-11: 8A00]P35367HRH1
T77913DI0349Pruritus[ICD-11: EC90]P35367HRH1
T77913DI0366Rheumatoid arthritis[ICD-11: FA20]P35367HRH1
T77913DI0388Sleep-wake disorder[ICD-11: 7A00-7B2Z]P35367HRH1
T77913DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]P35367HRH1
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T46828DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P21918DRD5
T99799DI0324Pain[ICD-11: MG30-MG3Z]P06276BCHE
T99799DI0411Tonus and reflex abnormality[ICD-11: MB47]P06276BCHE
T92609DI0190Hypertension[ICD-11: BA00-BA04]P35348ADRA1A
T92609DI0348Prostate hyperplasia[ICD-11: GA90]P35348ADRA1A
T09538DI0164Genetic prion disease[ICD-11: 8E02]P05186ALPL
T09538DI0330Parasitic infection[ICD-11: 1D0Y-1G2Z]P05186ALPL
T33489DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P08842STS
T11451DI0095Colorectal cancer[ICD-11: 2B91]Q9NR96TLR9
T11451DI0179Hepatitis virus infection[ICD-11: 1E50-1E51]Q9NR96TLR9
T11451DI0252Melanoma[ICD-11: 2C30]Q9NR96TLR9
T11451DI0346Prostate cancer[ICD-11: 2C82]Q9NR96TLR9
T64591DI0087Chronic pain[ICD-11: MG30]P46098HTR3A
T64591DI0101Corneal disease[ICD-11: 9A76-9A78]P46098HTR3A
T64591DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P46098HTR3A
T64591DI0218Irritable bowel syndrome[ICD-11: DD91]P46098HTR3A
T64591DI0293Nausea/vomiting[ICD-11: MD90]P46098HTR3A
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1
T81735DI0360Rectum cancer[ICD-11: 2B92]P78527PRKDC
T81735DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P78527PRKDC
T17569DI0030Angina pectoris[ICD-11: BA40]P22460KCNA5
T76914DI0198Idiopathic inflammatory myopathy[ICD-11: 4A41]P22001KCNA3
T76914DI0351Psoriasis[ICD-11: EA90]P22001KCNA3
T76914DI0352Psoriatic arthritis[ICD-11: FA21]P22001KCNA3
T06955DI0283Mycosis fungoides[ICD-11: 2B01]P51679CCR4
T06955DI0379Sezary syndrome[ICD-11: 2B02]P51679CCR4
T11911DI0285Myelopathy[ICD-11: 8B42]Q92952KCNN1
T59881DI0009Acute diabete complication[ICD-11: 5A2Y]P47901AVPR1B
T59881DI0041Autism spectrum disorder[ICD-11: 6A02]P47901AVPR1B
T59881DI0194Hypo-osmolality/hyponatraemia[ICD-11: 5C72]P47901AVPR1B
T86271DI0285Myelopathy[ICD-11: 8B42]Q9H2S1KCNN2
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025